tradingkey.logo
搜尋

Liminatus Pharma Ord Shs Class A

LIMN
添加自選
2.990USD
+0.220+7.94%
收盤 11-13 16:00(美東)
4.01M總市值
虧損本益比TTM

關於 Liminatus Pharma Ord Shs Class A 公司

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Liminatus Pharma Ord Shs Class A 簡介

公司代碼- -
公司名稱- -
上市日期- -
CEO- -
員工數量- -
證券類型- -
年結日- -
公司地址- -
城市- -
上市交易所- -
國家- -
郵編- -
電話- -
網址- -
公司代碼- -
上市日期- -
CEO- -

Liminatus Pharma Ord Shs Class A公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Byong Chul Yoo, Ph.D.
Dr. Byong Chul Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Beom K. Choi
Dr. Beom K. Choi
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Philip Lemons
Mr. Philip Lemons
Independent Director
Independent Director
--
--
Mr. Richard Baek
Mr. Richard Baek
Independent Director
Independent Director
--
--
Mr. Chris Kim
Mr. Chris Kim
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Philip Lemons
Mr. Philip Lemons
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Mr. Nicholas Fernandez
Mr. Nicholas Fernandez
Independent Director
Independent Director
333.00
--
Dr. Eun Sook Lee, M.D., Ph.D.
Dr. Eun Sook Lee, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Byong Chul Yoo, Ph.D.
Dr. Byong Chul Yoo, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Beom K. Choi
Dr. Beom K. Choi
Chief Technology Officer
Chief Technology Officer
--
--

常見問題

Liminatus Pharma Ord Shs Class A的前五大股東是誰?

Liminatus Pharma Ord Shs Class A的前五大股東如下:Mr. Nicholas Fernandez
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有